MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Intrathecal Administration of Autologous Mesenchymal Stem Cells in Multiple System Atrophy – A Phase I/II Dose-Escalation Trial

W. Singer, A. Dietz, A. Zeller, T. Gehrking, J. Schmelzer, D. Sletten, J. Gehrking, E. Coon, P. Sandroni, E. Benarroch, R. Fealey, J. Matsumoto, J. Bower, J. Ahlskog, A. Hassan, A. McKeon, B. Klassen, P. Low (Rochester, MN, USA)

Meeting: 2017 International Congress

Abstract Number: 229

Keywords: Multiple system atrophy(MSA): Treatment

Session Information

Date: Monday, June 5, 2017

Session Title: Parkinsonism, MSA, PSP (Secondary and Parkinsonism-Plus)

Session Time: 1:45pm-3:15pm

Location: Exhibit Hall C

Objective: To explore intrathecal administration of autologous mesenchymal stem cells (MSCs) as therapeutic approach to multiple system atrophy (MSA).

Background: MSA is a rapidly progressive neurodegenerative disease for which there is no proven disease-modifying treatment. Recent insights into pathophysiologic mechanisms suggest a critical role of deprivation of neurotrophic factors which have been shown to be secreted by MSCs.

Methods: Utilizing a dose-escalation design we delivered adipose-derived autologous MSCs intrathecally via lumbar puncture to patients with early MSA. Between 10 and 200 million MSCs were administered in three predefined dose tiers and patients were closely followed for one year with serial clinical, laboratory, and MRI surveillance. Primary endpoints were frequency and type of adverse events; secondary endpoints were the rate of disease progression assessed by the Unified MSA Rating Scale (UMSARS) and indices of autonomic function. A Bayesian approach utilizing the placebo group of our recently completed Rifampicin treatment trial allowed for assessment of potential efficacy.

Results: 24 patients were enrolled. There were no attributable serious adverse events and the procedure was generally well tolerated. At the highest dose tier, 3 of 4 patients developed low back/thigh pain, associated with thickening/enhancement of lumbar nerve roots and variable elevation of CSF protein and cell count. Although there were no associated neurologic deficits, we decided that dose-limiting toxicity was reached. 5 of 12 patients in the medium dose-tier developed similar, but milder and transient discomfort. Rate of progression (UMSARS Total) was markedly lower compared to the placebo group (0.43±0.59 versus 1.22±1.30 points/month, p=0.009); this difference was more pronounced for the medium than the low dose-tier.

Conclusions: Intrathecal MSC administration in MSA is safe and well tolerated but can be associated with a painful “implantation response” at high doses. The apparent dose-dependent slowing of disease progression is highly intriguing and the basis for a planned placebo-controlled phase II/III study.

Supported by NIH (P01NS44233, U54NS065736, K23NS075141, R01FD004789, R01NS092625, UL1TR000135), Cure MSA Foundation, and Mayo Funds.

To cite this abstract in AMA style:

W. Singer, A. Dietz, A. Zeller, T. Gehrking, J. Schmelzer, D. Sletten, J. Gehrking, E. Coon, P. Sandroni, E. Benarroch, R. Fealey, J. Matsumoto, J. Bower, J. Ahlskog, A. Hassan, A. McKeon, B. Klassen, P. Low. Intrathecal Administration of Autologous Mesenchymal Stem Cells in Multiple System Atrophy – A Phase I/II Dose-Escalation Trial [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/intrathecal-administration-of-autologous-mesenchymal-stem-cells-in-multiple-system-atrophy-a-phase-iii-dose-escalation-trial/. Accessed May 13, 2025.
  • Tweet
  • Email
  • Print

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/intrathecal-administration-of-autologous-mesenchymal-stem-cells-in-multiple-system-atrophy-a-phase-iii-dose-escalation-trial/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • #23624 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Three cases of early tremor in the course of Guillain-Barré Syndrome
  • The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley